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Two-stage hepatocarcinogenesis models in
rats are useful in identifying tumor-pro-
moting activity ofchemicals by stereologic
quantification ofaltered hepatocellular foci
(1,2). In addition, chemically induced cell
proliferation may play a critical role in the
development of cancer, especially for
chemicals that appear to act by nongeno-
toxic mechanisms (3-6). 2,3,7,8-Tetra-
chlorodibenzo-p-dioxin (TCDD), a hepa-
tocarcinogen in female rats (7,8), is gener-
ally regarded as a nongenotoxic carcinogen
(9-11) and has been identified as a potent
tumor promoter in two-stage rat liver
tumor models with negligible tumor-initi-
ating potential (12-14). Most risk assess-
ments for estimating human health risks
from TCDD exposure are derived from
tumor incidence data in female rat liver
(15).
Although mechanisms for the carcino-
genic activity of TCDD and its structural
analogs are unknown, many toxic and bio-
chemical effects of TCDD appear to
require the Ah receptor, including effects
on signal transduction pathways possibly
involving epidermal growth factor receptor
(16,17) and estrogen receptor (18,19).
Induction of liver tumors in female rats
treated with TCDD is associated with
enhanced hepatocyte proliferation and is
modulated by ovarian hormones (20).
Because cell proliferation may play a role
in the carcinogenic process and because
evaluation ofaltered hepatic foci (AHF) is
useful in identifying hepatocarcinogens,
information on dose-response relation-
ships for these effects within the frame-
work of a two-stage model for hepatocar-
cinogenesis may provide essential informa-
tion for estimating cancer risks from dioxin
exposure.
Unfortunately, there is no information
in the literature on dose-response relation-
ships for TCDD's effects on cell prolifera-
tion either in hepatocytes or within AHF,
although stereological measures of
enzyme-altered foci have been reported
(12). However, there is considerable data
on dose-response relationships for induc-
tion of two cytochrome P450 isozymes
(CYPlAl and 1A2) in rat liver (9,21-23).
Although the mechanistic link between
P450 induction and cell proliferation or
cancer is not readily apparent, we have
compared dose-response relationships for
these different endpoints to evaluate rela-
tive sensitivities for various responses to
TCDD within the framework of a tumor
promotion model.
In the present studies, we used a two-
stage model for hepatocarcinogenesis in
female Sprague-Dawley rats to determine
the dose response ofTCDD promotion, as
measured by histologic and biochemical
parameters, after initiation with a single
dose of diethylnitrosamine (DEN). After
30 weeks of TCDD treatment, several
parameters were assessed including histo-
pathology, AHF positive for the placental
isozyme of glutathione S-transferase
(PGST), hepatocyte proliferation, and
liver TCDD concentrations. We evaluated
dose-response relationships on the basis of
both administered dose and target tissue
dose of total (free plus bound) TCDD.
Furthermore, dose-response relationships
for PGST+ foci and hepatocyte prolifera-
tion were compared to those for CYPTlAl
and CYP1A2 induction in the same livers
to determine ifenzyme induction is corre-
lated with effects on cell proliferation and
size and number of PGST+ foci. In addi-
tion, we compared cell proliferation rates
in focal lesions to those in normal hepato-
cytes to assess TCDD's effects on selective
growth enhancement of putative precur-
sors of neoplastic lesions. These studies
revealed that there was considerable inter-
individual variation in TCDD's effects on
hepatocyte proliferation, various parame-
ters of PGST+ foci, and histomorphologic
alterations. It appears that these biological
responses occur at higher TCDD expo-
sures than previously reported for CYPlAI
and CYP1A2 induction in rat liver (22).
Materials and Methods
Female Sprague-Dawley rats, used because
of a previous carcinogenicity bioassay (7)
and liver tumor promotion studies (12,24),
were obtained from Charles River Breeding
Laboratories, Inc. (Raleigh, North Caro-
lina), acclimatized for 2 weeks, and ran-
domly distributed into 1 of 10 treatment
groups on the basis of body weight. The
treatment groups consisted offour separate
doses ofTCDD after initiation with DEN
and appropriate noninitiated and vehicle
controls as detailed in Table 1. At 70 days
of age, 175 mg DEN/kg body weight was
administered intraperitoneally as the initi-
ating agent with 1 pl saline/g body weight
as the DEN vehicle control. Starting 2
weeks after initiation, rats were given
TCDD by gavage in corn oil once every 2
weeks for 30 weeks. Biweekly doses ranged
from 49 to 1750 ng TCDD/kg and are
considered equivalent to 3.5 to 125 ng
TCDD/kg body weight/day. Rats were
killed 7 days after the final treatment.
There were 8-10 rats/group. The high dose
was previously shown to promote liver
tumors in DEN-initiated rats (24).
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Table 1. Final body weight(BW), liverweight(LW), and hepatocyte labeling index(LI) in female Sprague-
Dawley rats
Bodyweight Liverweight LW/BW
Treatment group n (g)a (g)a (x 100),b Ll(%)c
DEN/corn oil 10 391 ± 45 12.7 ± 1.4 3.3 ± 0.3 5.28 ± 2.22
DEN/TCDD (3.5 ng/kg) 9 387 ± 43 13.3 ± 2.6 3.4 ± 0.4 3.28 ± 1.55*
DEN/TCDD (10.7 ng/kg) 9 390 ± 71 14.1 ± 2.4 3.6 ± 0.3 3.25 ± 2.91
DEN/TCDD (35.7 ng/kg) 8 355 ± 37 13.4 ± 1.1 3.8 ± 0.3 6.39 ± 3.62
DEN/TCDD (125 ng/kg) 9 362 ± 68 16.0 ± 2.4 4.5 ± 0.3 14.35 ± 8.26
Saline/corn oil 9 442 ±47d 14.9 ± 2.1 3.4 ± 0.2d 3.41 ± 1.97
Saline/TCDD (3.5 ng/kg) 9 399 ± 38 13.9 ± 1.7 3.5 ± 0.2 3.22 ± 2.16
Saline/TCDD (10.7 ng/kg) 9 402 ± 67 14.3 ± 2.0 3.6 ± 0.3 4.87 ± 5.66
Saline/TCDD (35.7 ng/kg) 9 433 ±88* 16.5 ± 3.9 3.8 ±0.5* 5.33 ± 5.82
Saline/TCDD (125 ng/kg) 9 346 ± 34 15.1 ± 4.7 4.3 ± 1.2 7.09 ± 8.15
DEN, diethyinitrosamine; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
aTCDD effect and initiation effectsignificant (p<0.05) in analysis ofvariance.
L'TCDD effect significant (p< 0.05) in analysis ofvariance.
CTCDD effect and interaction between TCDD and initiation significant(p<0.05) in analysis ofvariance.
d < 0.05 fortrend test using a general linear model.
Statistically significant versus control as measured bytwo-tailed, unpaired Student's-ttest, p< 0.05.
We weighed the liver at necropsy and
froze representative samples of the left and
right median, left lateral, and right posteri-
or lobes in liquid nitrogen or fixed them in
10% formalin for routine hematoxylin and
eosin staining and histopathologic evalua-
tion using published diagnostic criteria
(25). A section ofduodenum was also saved
and embedded along with the fixed liver
sections as a positive control for the cell
proliferation studies. Histologic sections of
liver were stained for PGST using an
immunohistochemical procedure (26). A
minimum of eight contiguous PGST+
hepatocytes was required for a PGST+ focus
to be scored. Foci were quantified using
computer-assisted image analysis (NIH
Image V3.8 for the Macintosh by W.
Rasband, NIH) and subjected to stereologi-
cal analysis as described previously (27,28).
We estimated the number and size ofAHF
in H&E-stained sections and the relative
degree oftoxicity based on a semiquantita-
tive grading scale (seeTable 3 fordetails).
Immediately before euthanizing the
rats, blood was collected under carbon
dioxide anesthesia by cardiac puncture
using a 20-gauge needle and a 10-ml
syringe. Blood was transferred to prelabeled
serum separator tubes without anticoagu-
lant, and sera were harvested from the clot-
ted blood within 30 min ofcollection. The
following clinical chemistry measurements
were made using a Monarch 2000 (Instru-
mentation Laboratories, Inc., Lexington,
Massachusetts) and commercially available
reagents: alkaline phosphatase (AP), glu-
cose, alanine aminotransferase (ALT), total
cholesterol, triglycerides, sorbitol dehydro-
genase (SDH), 5'-nucleotidase (5'-Nuc),
and total bile acids. Sera were stored at -
700C between collection and measure-
ments.
Replicative DNA synthesis (S-phase
hepatocytes) was immunohistochemically
quantified by identifying bromodeoxyuri-
dine (BrdU) incorporation after subcuta-
neous implantation -of a 7-day osmotic
minipump (Alzet model 2ML1; 10 pl/hr;
Alzet Corp., Palo Alto, California) filled
with 30 mg/ml BrdU in distilled water.
We surgically implanted minipumps 7
days before sacrifice while rats were under
methoxyfluorane/oxygen inhalation anes-
thesia. Incorporation of BrdU was quanti-
fied in immunohistochemically stained sec-
tions (29) by counting labeled nuclei
among at least 1000 hepatocytes in ran-
domly selected fields. For determination of
hepatic cell proliferation indices among
various treatment groups, care was taken to
avoid AHF in the fields counted. A label-
ing index was generated by dividing the
number oflabeled hepatocytes by the total
number of hepatocytes counted, and the
result was expressed as a percentage. Before
counting, written criteria for scoring were
used by four independent observers to
determining the labeling index for three
rats. There was close agreement in the
independently determined labeling indices.
The lobular distribution of S-phase hepa-
tocytes was noted in most cases, although
this was not done for some livers with only
a small number oflabeled cells.
Labeling indices determined from
slides stained immunohistochemically for
proliferating cell nuclear antigen (PCNA)
(30,31) and counterstained with H&E
were evaluated in 10-12 AHF from rats
given DEN followed by corn oil or one of
the TCDD treatment regimens. Positive
staining was evaluated in 90-100% of the
hepatocytes in each focal transection
according to previously published criteria
(30,31). All foci evaluated were clearly dis-
cernible and were randomly selected as
representative medium-sized, clear-cell
AHF (0.3-1.25 mm in diameter) as mea-
sured using a calibrated eyepiece reticule.
We calculated a PCNA S-phase labeling
index plus a growth fraction (the propor-
tion ofcells in GI, S-phase, G2, and mito-
sis combined) for each AHF evaluated. We
analyzed 1-g samples of liver for TCDD
concentrations by GC-MS as previously
reported (20).
Results
Body and LiverWeight
At the end ofthe study, body weight gain
was statistically significantly lower than
controls in the noninitiated group that
received 125 ng TCDD/kg body weight/
day. There was a nonsignificant treatment-
related decreased trend in body weight in
initiated rats (p = 0.18) and a significant
decrease in bodyweight in the noninitiated
rats (p = 0.004). Data are presented in
Table 1 and illustrated in Figure 1. A con-
tinuous mathematical model was fit to
these data to give an indication ofTCDD-
induced changes in overall body weight. A
model which fit the datawell is:
Vna tE(aa) max
W(t,da)= + C
Km+ t
where W4t,a) is the expected weight of an
animal exposed to dose level d of TCDD
(ng/kg/day) at day t, C is the expected
weight at the start of the experiment, and
Vmax, Km, and a are parameters of the
model. E (Euler's constant) = 2.71828.
The estimated values ofthe model parame-
ters are C = 237.3 g (± 4.4 SE), V =ax=
219.7 (± 15.73), Km= 116.3 (± 22.94)
days, and a -2.86 x 10-3 (± 3.57 x 10-)
(ng/kg/day)Y. The effect ofdose (a) is sig-
nificantly different from 0 (p < 0.05).
There was a statistically significant
effect ofTCDD and initiation on absolute
liver weight. This trend was obvious in the
DEN initiated rats, but less notable in the
saline-treated rats. When liver weight rela-
tive to bodyweight was analyzed, the effect
of initiation disappeared and the TCDD
dose response became apparent and effec-
tively equal in the initiated and noninitiat-
ed groups. Relative liver weight was statis-
tically increased over controls in rats treat-
ed with > 10.7 ng TCDD/kg body
weight/day in the initiated animals and in
rats treated with 2 35.7 ng TCDD/kg
body weight/day in the noninitiated ani-
mals. The ratio of liver weight to body
weight can also be modeled using a simple
form given by:
Vmax d
R(a) K + C
Km+ d
where R(d) is (liver weight/body weight) x
100% at dose d(ng/kg/day), Cis the ratio
in control animals and Vmax and Km are
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Figure 2. Effect of TCDD on the ratio of the liver
weight to the bodyweight.
dose-response changes due to TCDD were
seen for AP, total cholesterol, triglycerides,
SDH, and 5'-Nuc. In addition, significant
effects of initiation were seen for AP and
triglycerides and a marginally significant
effect on SDH (p = 0.058) was seen. There
were no statistically significant interactions
between DEN and TCDD for atny of the
serum chemistry measurements, although
many of the measures showed similar high
dose responses but significantly different
control responses between initiated and
noninitiated rats. ALT was marginally
affected by TCDD (p = 0.087) with a
slight interaction between TCDD and
DEN (p = 0.073) and with statistically
increased response over control in the two
highest dose groups of initiated rats.
Glucose and total bile acids were unaffect-
ed by either TCDD or DEN treatments.
The elevations ofALT, AP, 5'-Nuc, and
SDH are consistent with the cytotoxicity
observed inhistologic sections.
Histopathology
Histologic evidence oftoxicity consisted of
cytoplasmic vacuolization, fatty change,
bile duct hyperplasia, and pigment in
Kupffer cells and is documented for indi-
vidual rats in Table 3. There was a dose-
related increase in toxicity in both initiated
and noninitiated rats, with somewhat
greater severity oftoxicity in noninitiated
rats. An estimate ofAHF as detected in
H&E-stained sections based on number
and size is also presented in Table 3 for
individual rats. Rats initiated with DEN
had more AHF in H&E-stained sections
than noninitiated rats. Most AHF were
clear cell, acidophilic, or basophilic. There
was no strong positive or negative correla-
tion between individual rat BrdU S-phase
hepatocyte labeling index (LI) and H&E-
stainedAHF (r= 0.321 for initiated and r=
0.433 for noninitiated rats) or between
labeling index and toxicity (r = 0.533 for
initiated and r = 0.451 for noninitiated
rats). Likewise, there was no cear correla-
E
co
03
Dayso Study
mo _mfgwg _~
Days onStudy
parameters. For the data given here, esti-
mates are C = 3.361 (± 0.0815)%, V =
1.792 (± 0.692)%, and Km = 92.31 (±
80.16) ng/kg/day. The fit of this model to
the data is illustrated in Figure 2. The
value of Vmax is significantly different from
zero (p < 0.05), indicating the significant
effect of treatment on this ratio. The maxi-
mum change indicated by the model is
1.792% for a large treatment dose. At 125
ngTCDD/kg bodyweight/day, the change
over control is 1.03%.
Gross Lesions
Livers from rats treated with either 35.7 or
125 ng TCDD/kg body weight/day were
either uniformly darker than normal or
O In 3m
DaysonStudy
Figure 1. (above and left) The effects of TCDD on
body weight as a function of age and level of
exposure.
had 2-5 mm irregularly round, dark areas
on all natural surfaces. A 3-mm tan focus,
diagnosed as a hepatocellular adenoma,
was observed on a cut surface of the left
median lobe of a rat in the DEN/TCDD
(125 ng/kg) group, and a 10-mm tan nod-
ule, diagnosed as focal fibrosis, was present
on the left median lobe of a rat in the
DEN/TCDD (35.7 ng/kg) group. Biliary
cysts were present in the livers of two rats,
one from the DEN/TCDD (10.7 ng/kg)
group and the other from the DEN/TCDD
(125 ng/kg) group. Livers from all other
rats were macroscopically normal. The fre-
quency of hepatocellular proliferative
lesions is not significantly different from
that which might be expected in controls
at a 30-week time point. Biliary cysts com-
monly occur in TCDD-treated rats (un-
published observations). Based upon previ-
ous studies, liver tumor incidence was
increased after a total of60 weeks of treat-
ment with TCDD (125 ng/kg/day) in
DEN-initiated rats (24).
Clinical Pathology
Means, standard deviations, and the analy-
sis ofthe serum chemistry data are present-
ed in Table 2. Statistically significant
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Table 2. Serum clinical chemistry parameters from female Sprague-Dawley rats
AP Glucose ALT Total cholestrol Triglycerides SDH 5'-Nuc TBA
Group (lU/I)a (mg/dl) (lU/I) (mg/dl)b (mg/dl)8 (Ul/l)b (lUll)a (,umol/l)
DEN/corn oil 75.5 ± 25.9c 156.0 ± 15.4 23.3 ± 5.6c 102.6 ± 21.5c 303.2 ± 129.7c 17.1 ± 8.8c 30.5 ± 6.0c 40.98 ± 26.80
DEN/TCDD (3.5 ng/kg) 75.2 ± 26.1 150.7 ± 10.2 28.9 ± 14.1 106.7 ± 22.0 374.9 ± 146.7 21.4 ± 10.5 31.7 ± 10.7 45.01 ± 29.57
DEN/TCDD (10.7ng/kg) 76.6 ± 21.8 154.7 ± 17.8 34.9 ±25.5* 118.7 ±12.2* 298.1 ± 92.9 22.9 ± 22.0* 39.9 ± 17.9 29.71 ± 13.20
DEN/TCDD (35.7 ng/kg) 98.0 ± 25.8 149.0 ± 25.6 35.5 ± 12.1 134.4 ± 12.3 284.3 ± 79.7 29.6 ± 12.0 47.0 ± 26.6 41.34 ± 8.58
DEN/TCDD (125 ng/kg) 151.7 ± 49.1 145.1 ± 14.2 41.4± 14.8 141.6 ± 25.9 208.0 ± 82.7 38.2± 11.0 48.8± 10.3 52.89 ± 28.14
Saline/corn oil 99.0 ±46.3c 144.0 ± 8.6 37.7 ± 14.3 106.2 ± 17.2c 432.7 ± 105.9 29.6 ± 15.4 35.2 ± 6.2c 32.30 ± 13.15
Saline/TCDD (3.5 ng/kg) 104.0 ± 55.9 160.2 ± 18.1 28.9 ± 9.6 96.3 ± 10.8 354.9 ± 144.8 25.8 ± 14.9 32.9 ± 11.5 43.77 ± 24.34
Saline/TCDD (10.7 ng/kg) 99.3 ± 68.3 165.4 ±22.0* 34.9 ± 8.4 111.4 ± 29.9 403.1 ± 191.8 24.1 ± 8.8 32.7 ± 6.6 42.84 ± 25.51
Saline/TCDD (35.7 ng/kg) 117.0 ± 84.8 156.3 ± 13.2 35.2 ± 8.6 132.9 ± 33.9 486.3 ± 379.8 31.1 ± 12.3 51.0 ± 20.5 30.11 ± 7.04
Saline/TCDD (125 ng/kg) 151.4 ± 55.2 154.7 ± 17.6 33.6 ± 7.0 144.8 ± 27.2 316.6 ± 96.5 33.4± 9.6 56.1 ± 21.1 42.11 ± 19.25
AP, alkaline phosphatase; ALT, alanine aminotransferase; SDH, sorbitol dehydrogenase; 5'-Nuc, 5'-nucleotidase; TBA,total bile acids; DEN, diethylnitrosamine;
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
aTCDD effect and initiation effectsignificant (p<0.05) in analysis ofvariance.
bTCDD effectsignificant (p<0.05) in analysis ofvariance.
cp<0.05fortrend testusing a general linear model.
Statistically significant versus control as measured bytwo-tailed, unpaired Student's-ttest, p <0.05.
tion between the presence ofH&E-stained
AHF and toxicity (r = 0.206 for initiated
and r = 0.213 for noninitiated rats). The
highest mean BrdU LIs for non-AHF hepa-
tocytes were present in the groups receiving
the highest dose ofTCDD, even though LI
was poorly correlated with AHF or toxicity
on an individual rat basis.
Cell Proliferation
Mean BrdU hepatocyte LIs for the different
treatment groups are summarized in Table
1 and individual rat LIs are given in Table
3. For all rats initiated with DEN, BrdU+
S-phase nuclei were randomly distributed
throughout the hepatic lobules. In contrast,
there was a periportal distribution ofBrdU+
S-phase nuclei in several noninitiated
TCDD-treated rats (Table 3). Overall,
there was a statistically significant increased
trend in LI as a function ofdose ofTCDD
with an interaction between TCDD and
DEN. This trend suggests dose dependen-
cy, but the results when compared to the
controls are not statistically significant. The
trend in increasing LI was stronger in initi-
ated rats than in noninitiated rats. There
was a statistically significant decrease in LI
in the low-dose group ofinitiated rats. This
may be a reflection of the increased LI in
DEN-treated control rats; an increase
which is marginally significant (p = 0.07)
compared to the noninitiated controls.
The variability in LIs between rats
within a given dose group increased as the
dose of TCDD was increased and was
especially evident in the 125 ng/kg dose
group, where there were rats with a clearly
elevated LI and other rats which were not
different from controls (Fig. 3). This vari-
ability was also evident when individual rat
LIs were plotted against the liver concen-
tration ofTCDD (Fig. 4).
PCNA + S-phase hepatocyte LIs were
enumerated within AHF evident in H&E-
stained sections from DEN-initiated rats,
and the results for individual AHF are pre-
sented along with the growth fraction and
the AHF diameter in Table 4. It was
apparent that most AHF generally had a
higher S-phase LI and growth fraction
than the surrounding nonfocal hepatocytes
(data not presented). There was no clear
correlation between AHF diameter and
PCNA + S-phase LI (r = 0.157) or growth
fraction (r = 0.217), whereas the correla-
tion between PCNA + S-phase and growth
fraction was r = 0.822). No significant
treatment-related effect on either S-phase
(p = 0.520) or growth fraction (p = 0.676)
LI was found for AHF based on analysis of
variance; thus, TCDD treatment did not
increase the LI within AHF selected for
evaluation.
PGST+ Foci ofCellularAlteration
Stereologic results obtained from quantifi-
cation ofAHF positively stained for PGST
are summarized in Table 5. All five mea-
sures in Table 5 showed a highly signifi-
cant effect (p < 0.01) of initiation when
analyzed in the analysis of variance. The
number offoci/cm2, volume fraction, and
mean focal volume also showed significant
TCDD dose-response trends (p < 0.05)
and significant interaction between TCDD
and DEN (p < 0.05). For all calculated
parameters, rats initiated with DEN had
higher values than comparable noninitiat-
ed groups. This expresses itselfas a signifi-
cant initiation effect for all five measures.
Among the DEN-initiated groups there
was a significant dose-related increase in
foci/cm , volume fraction, and mean focus
volume. The absence of a significant
increase in foci/cm3 is a consequence ofthe
125 ng TCDD group having larger foci, as
reflected by the mean focus volume. There
were no individual significant dose-related
increases in PGST' focus stereological
parameters in the noninitiated rat groups.
This lack ofsignificance is due to a reduc-
tion in,focal lesion production in the high
exposure noninitiated group.
Although the PGST+ focus response
shows a clear treatment-related response,
when individual rat stereological calcula-
tions such as focus size are plotted against
administered dose ofTCDD, there is obvi-
ous variability in this response with one or
two rats in each TCDD-treated group
being especially responsive (Fig. 5). The
correlation between focus size and liver
concentration ofTCDD is somewhat bet-
ter (Fig. 6) but still demonstrates individ-
ual rat variability. Other stereological para-
meters such as numbers offoci and volume
fraction show similar responses and vari-
ability to that demonstrated for focus size
in Figures 5 and 6.
Hepatic TCDD Concentrations
TCDD concentrations in liver were quan-
tified only in DEN/TCDD-treated rats
because previous studies had demonstrated
that TCDD concentrations were similar in
DEN-initiated and in noninitiated rats
(20). In general, within the dose range
used (3.5-125 ng TCDD/kg/day) there
was a linear relationship between adminis-
tered dose and liver concentration whether
TCDD levels were based on liver wet
weight or liver lipid (Fig. 7) (22). Average
values on a wet-weight basis were approxi-
mately 0.5 ppb in the 3.5 ng/kg dose
group and approximately 20 ppb in the
125 ng/kg dose group.
Discussion
Two-stage hepatocarcinogenesis models in
rats may be used to test the tumor promo-
tion ability of a chemical (1). The first
morphologic indication of a chemically
induced carcinogenic process in rat liver is
the appearance of putatively preneoplastic
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Table 3. Bromodeoxyuridine S-phase labeling indices (BrdU LI), altered hepatic foci (AHF), and toxicity
Group Animal ID BrdU LI(%)a AHFb Toxicityc Group AnimalID BrdU LI (%)a AHFb Toxicityc
DEN/corn oil 1-1 7.69r 2 0 Saline/corn oil 19-1 5.71c 0 0
DEN/3.5 ng TCDD/kg/day
DEN/10.7 ng TCDD/kg/day
DEN/35.7 ng TCDD/kg/day
DEN/125 ng TCDD/kg/day
1-2 3.70r
1-3 2.30r
1-4 3.31r
2-1 5.41r
2-2 4.32r
2-3 3.13r
3-1 8.48r
3-2 7.03r
3-3 7.38r
4-1 3.34r
4-2 5.61r
4-3 5.65r
5-1 4.20r
5-2 2.38r
5-3 2.66r
6-1 1.77
6-2 2.32r
6-3 1.59
7-1 1.96
7-2 0.2
7-3 lO.lOr
8-1 3.48r
8-2 2.89r
8-3 2.91r
9-1 1.90r
9-2 2.30r
9-3 0.49
10-1 5. 1r
10-2 6.10r
10-3 1.37r
11-1 8.58r
11-2 3.82r
1i-3 13.65r
12-1 5.73r
12-2 6.57r
13-1 8.86r
13-2 21.96r
14-1 7.25r
14-2 21.35r
14-3 5.91r
17-1 10.92r
17-2 5.99r
18-1 27.97r
18-2 19.21r
3 0
1 0
2 0
1 0
1 0
1 0
2 0
2 0
3 0
2 0
2 0
1 0
3 1
3 2
3 0
2 0
3 1
2 0
1 0
0 2
3 0
0 1
1 0
3 1
1 0
3 0
2 0
2 0
3 0
2 2
1 3
0 3
2 3
3 3
3 3
3 3
2 3
3 2
3 4
3 2
3 2
3 2
3 2
3 4
Saline/3.5 ng TCDD/kg/day
Saline/i0.7 ng TCDD/kg/day
Saline/35.7 ng TCDD/kg/day
Saline/125 ng TCDD/kg/day
19-2
19-3
20-1
20-2
20-3
21-1
21-2
21-3
22-1
22-2
22-3
23-1
23-2
23-3
24-1
24-2
24-3
4.59r
5.36r
0.97
2.45r
3.22r
5.61p
1.77
0.99
2.81m
0.62
1.75
0.98
1.81r
6.42r
3.59r
5.87r
5.16p
25-1 19.29c
25-2 2.57p
25-3 5.02p
26-1 1.86p
26-2 1.43p
26-3 4.41p
27-1 5.76m
27-2 0.85
27-3 2.60p
28-1 9.07r
28-2 3.28p
28-3 3.30p
29-1 0.34r
29-2 2.49m
29-3 0.14
30-1 0.53
30-2 14.89c
30-3 13.96p
31-1
31-2
31-3
32-1
32-2
32-3
33-1
33-2
33-3
23.64p
3.91c
4.41p
1.22
1.07p
9.20r
1.46p
1.67
17.26c
aDistribution of labeled nuclei: r, random; c, centrilobular; p, periportal; m, midlobular. For some low labeling indices, it was not possible to determine a clear dis-
tribution pattern of labeled nuclei.
bAltered hepatic focus response on hematoxylin & eosin stained sections: 0 = no foci; 1 = a fewfoci; 2 = moderate number offoci; 3 = many foci.
CToxicity: Severity grades range from 0 = no toxicity to 6 = most severe toxicity observed. Toxicity characterized by cytoplasmic vacuolization, fatty change, bile
duct hyperplasia, and/or pigment in Kupffer cells.
.5
ph-
norema h_eptof difern ds ofTD on the
brmdoyrdn S_-phs labelin St g ine inaIa
noma heptoyts E----;X|gfi.
KA
a
.a .a
I 10 D 3D
UverConcmmiron lppb)
Figure 4. Effect of liver concentrations of TCDD
on the bromodeoxyuridine S-phase labeling index
in normal hepatocytes.
AHF (32). In rats, enzyme histochemical
staining for the placental form of glu-
tathione S-transferase is considered a reli-
able marker for preneoplastic lesions of
hepatocytes (33). Enhancement ofAHF in
such initiation-promotion models could be
considered a reflection of tumor promo-
tion (34,35), as hepatic tumor promoters
are known to accelerate the appearance of
AHF (1) and are able to increase the num-
ber and/or size of AHF at a given time
interval (34,36).
As has been previously demonstrated
(20), initiation with a necrogenic dose of
DEN followed by treatment with 125 ng
TCDD/kg body weight/day resulted in
development of PGST+ foci. Further con-
firmation that TCDD acted as a promoter
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638of putative preneoplastic foci was evident
from the significant dose-related increase
in PGST+ AHF in the TCDD-treated rats
as well as increased size and number of
AHF noted in H&E-stained sections.
Similar to previous results, few PGST+ or
H&E-stained AHF were present in the
TCDD-only treated groups. The increases
in number ofAHF in initiated rats and in
noninitiated rats (less the high dose group)
combined with the strong interaction term
between TCDD and DEN suggest a com-
plex effect ofTCDD.
Previous studies (22,37,38) examined
dose-response relationships for TCDD-
mediated induction of cytochrome P450
isozymes (CYPlAl and CYP1A2) within
the framework of the same liver tumor
promotion model described in the present
paper. The conclusion, based on both
experimental data and biologically based
mathematical models for TCDD's effects
on gene expression, was that there appears
to be a linear relationship between admin-
istered dose, liver TCDD concentrations,
and cytochrome P450 induction, even in
the low dose region used in this study.
Therefore, growth and number of preneo-
plastic lesions appears to occur at a higher
dose ofTCDD than CYPlAI or CYP1A2
induction and/or the methods for quanti-
fying putative preneoplastic lesions are
inherently less sensitive than are the meth-
ods used to quantify cytochrome P450
isozymes. CYPlAI and 1A2 induction rep-
resents a much simpler response, whereas
AHF induction takes significantly longer
and reflects a more complicated process.
This complexity of response for AHF
could account for the discrepancy in dose
responsiveness when compared to CYPlAl
and 1A2.
There was evidence of cytotoxicity in
TCDD-treated groups as supported by
histopathological changes, increase in rela-
tive liver weight, and alterations in serum
clinical chemistry. The morphological evi-
dence of hepatotoxicity was present in all
TCDD-treated groups and was more
marked in the higher dose groups. In gen-
eral, hepatocytes were enlarged and vacuo-
lated, without an obvious lobular pattern
in the distribution of these changes. The
morphological findings are supported by
the dose-related increases in relative liver
weight and by dose-related alterations in
clinical chemistry measurements. Changes
in serum cholesterol, AP, and 5'-Nuc are
generally reflective of cholestatic changes,
whereas changes in SDH and ALT are gen-
erally reflective ofperturbations in hepato-
cyte membrane integrity and leakage of
these enzymes into the blood. The increas-
es in serum glucose in the noninitiated
groups treated with TCDD may reflect
perturbation in glucose mobilization in the
Table 4. Proliferating cell nuclear antigen S-phase labeling index (PCNA LI) and growth fraction in
altered hepatic foci
Mean focus PCNA PCNA growth
Treatmenta IDb diameter (mm) Li (%) fraction (%)
0 ng TCDD/kg/day 1-la 0.50 10.71 19.64
1-lb 0.45 1.47 5.88
1-2a 0.69 2.42 9.68
1-2b 0.43 12.70 42.86
1-4a 0.75 21.09 31.25
1-4b 0.75 30.43 38.04
3-1 0.48 18.92 29.05
3-2a 0.33 2.67 9.33
3-2b 0.50 8.27 10.53
3-3a 0.28 54.05 83.78
3-3b 0.85 27.54 53.29
3-3c 1.25 36.23 62.32
Mean 0.61 18.88 32.97
SE 0.08 4.61 7.03
3.5 ng TCDD/kg/day 4-la 0.75 26.14 50.57
4-lb 0.50 13.10 29.17
5-1 0.63 26.53 52.38
5-3a 0.40 11.58 22.96
5-3b 0.50 8.22 11.64
5-3c 0.85 23.63 47.26
6-2a 0.50 3.38 6.76
6-2b 0.55 16.13 24.73
6-3a 0.35 10.91 19.09
6-3b 0.35 21.88 27.08
Mean 0.54 16.15 29.16
SE 0.05 2.54 5.10
10.7 ng TCDD/kg/day 7-1 0.30 8.75 16.25
7-3a 0.90 9.80 26.14
7-3b 0.50 21.69 45.78
7-3c 0.40 7.29 25.00
8-2 0.50 39.88 53.18
8-3a 0.45 18.87 39.62
8-3b 0.35 23.36 39.42
9-2a 0.45 1.72 13.79
9-2b 0.40 0.00 7.69
9-2c 0.65 3.14 36.48
9-2d 0.30 0.00 11.76
9-3 0.75 8.09 15.03
Mean 0.50 11.88 27.51
SE 0.05 3.45 4.34
35.7 ng TCDD/kg/day 10-2a 0.53 11.92 23.84
10-2b 0.90 2.99 37.72
10-2c 0.35 4.17 50.00
10-3a 0.58 0.00 3.07
10-3b 0.48 2.50 6.67
10-3c 0.48 14.29 17.86
11-1 0.60 16.78 26.57
11-3 0.38 4.84 12.90
12-la 0.53 21.83 40.85
12-lb 0.65 7.58 11.36
12-1c 0.65 2.33 6.20
2-1d 0.40 42.11 74.74
Mean 0.54 10.95 25.98
SE 0.04 3.44 6.19
125 ng TCDD/kg/day 13-la 0.48 39.00 63.00
13-1b 0.65 7.50 62.50
14-1 0.55 44.68 71.49
14-3a 0.70 4.39 8.77
14-3b 0.45 3.16 24.21
17-1 1.00 5.56 45.24
17-2a 0.78 2.56 6.41
17-2b 0.35 3.76 6.02
18-la 1.05 42.15 50.41
18-lb 0.70 35.85 44.34
18-2 0.95 10.53 30.70
Mean 0.70 18.10 37.55
SE 0.07 5.41 7.21
aAll rats initiated with diethylnitrosamine followed by biweekly corn oil or 2,3,7,8- tetrachlorodibenzo-p-
dioxin treatment.
bID numbers reflect cage number, rat number; a,b,c,d indicate focus identification.
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Table 5. Stereologic parameters for placental glutathione S-transferase-positive altered hepatic foci in
female Sprague-Dawley rats
Volume fraction Mean volume
Group Foci/cm2a Foci/cm3b (%)a (pm3 x 103)a Foci/liverb
DEN/corn oil 10.9 ± 7.Oc 442.2 ± 284.4 0.57 ± 0.44c 13 ± 6c 5748 ± 3923
DEN/TCDD (3.5 ng/kg) 18.4 ± 10.1 759.2 ± 482.0 0.85 ± 0.40 15 ± 12 10552 ± 7941
DEN/TCDD (10.7 ng/kg) 20.4± 18.0 791.7 ± 597.2 1.00 ± 1.16 11±4 11482±8879
DEN/TCDD (35.7 ng/kg) 15.6 ± 7.7 530.4 ± 294.8 0.93 ± 0.56 18 ± 7 7157 ± 3952
DEN/TCDD (125 ng/kg) 26.5 ± 15.7* 751.7 ± 428.4 2.23 ± 1.47* 30 ± 8* 11989 ± 6798*
Saline/corn oil 0.4 ± 0.5d 22.3 ± 29.0d 0.01 ± 0.01 3 ± 3 327 ± 418d
Saline/TCDD (3.5 ng/kg) 0.7 ± 1.8 35.9 ± 89.8 0.02 ± 0.05 6 ± 1 457 ± 1122
Saline/TCDD (10.7 ng/kg) 0.6 ± 0.8 34.7 ± 49.8 0.02 ± 0.03 5 ± 3 447 ± 614
Saline/TCDD (35.7 ng/kg) 1.8 ± 2.7 102.8 ± 131.1 0.06 ± 0.11 5 ± 6 1533 ± 1794
Saline/TCDD (125 ng/kg) 1.1 ± 1.6 51.9 ± 69.5 0.04 ± 0.07 5 ± 3 693 ± 921
DEN, diethylnitrosamine; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin.
aStatistically significant effects forTCDD and initiation with significant interaction between TCDD and
DEN (p<0.05) in analysis ofvariance.
bStatistically significant effect of DEN (p<0.05), no significant effect ofTCDD in analysis ofvariance.
Cp<0 .05fortrend test using a general linear model.
Trend is statistically significant when high dose is excluded (p<0.05).
*Statistically significant versus control as measured bytwo-tailed, unpaired Student's-ttest, p<0.05.
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Figure 5. Effect of different doses of TCDD on
size (pm3) of glutathione S-transferase-positive
altered hepatic foci in rats initiated with diethylni-
trosamine.
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Figure 6. Effect of liver concentrations of TCDD
on the size (pm3) of glutathione S-transferase-
positive altered hepatic foci in rats initiated with
diethyinitrosamine.
liver, although it is not apparent why simi-
lar changes were not detected in the initiat-
ed rats treated with TCDD. It is unclear
what role DEN is playing in the modifica-
tion of AP, triglycerides, and SDH. The
TCDD(nglkg/day)
Figure 7. Relationship between administered
dose and liver concentration ofTCDD in rats initi-
ated with diethylnitrosamine.
evidence of cytotoxicity was also generally
supported by the dose-related increase in
the rate of replicative DNA synthesis in
non-AHF areas ofthe liver, although there
was not a high correlation between LI and
toxicity for individual rats. The increased
BrdU S-phase LI in DEN-initiated rats
versus noninitiated rats may be a conse-
quence ofDEN treatment selecting a pop-
ulation ofhepatocytes with higher replica-
tive DNA synthesis than those typically
present in noninitiated rats.
In the present study, measures ofhepa-
tocellular proliferative activity within puta-
tive preneoplastic AHF were estimated in
DEN-initiated rats by immunohistochemi-
cal staining of PCNA. This permitted an
estimate ofboth S-phase hepatocytes with-
in AHF and also the proportion of focus
cells active in the cell cycle (growth frac-
tion). Neither of these parameters was sig-
nificantly influenced by TCDD treatment,
suggesting that TCDD does not markedly
alter baseline proliferative rates within
AHF. Because TCDD does provide a
selective growth advantage for AHF as evi-
denced by increased size of PGST+ AHF
(Table 5), it may be that this effect is a
result ofa decreased rate ofcell death with-
in AHF. Alternatively, the ratio ofS-phase
cells to growth fraction within AHF may
be greater than that in non-AHF hepato-
cytes (not measured in the present study),
imparting a selective growth advantage to
AHF versus the surrounding hepatic par-
enchyma. The wide variability in individ-
ual AHF proliferative activity within any
given experimental group as well as in a
given rat suggests that the growth rate of
AHF is neither uniform nor synchronized
and that AHF may independently respond
to positive or negative growth stimuli.
There has been considerable discussion
on the advisability of using dose-response
relationships for enzyme induction as a
surrogate for TCDD's effects on more
coordinated biological responses such as
cell proliferation or growth ofputative pre-
neoplastic lesions. Our data provide evi-
dence that CYPlAI and CYP1A2 induc-
tion may not be a reliable surrogate. First,
chronic TCDD doses of 3.5 and 10.5
ng/kg/day produce pronounced increases
in CYPlAI and CYP1A2 protein concen-
trations and associated enzyme activity
(22), whereas data reported here indicate
less steep responses for replicative DNA
synthesis rates in normal hepatocytes.
Second, immunolocalization of hepatic
CYPlAl and CYP1A2 induction revealed
that induction occurs primarily in the cen-
trilobular region (22), whereas our data
reveal that cell proliferation in response to
TCDD occurred randomly or, in some
noninitiated rats, preferentially in the peri-
portal region. Consistent with our evi-
dence on the disassociation between toxic
responses and P450 enzyme induction is a
recent report by Clark et al. (24) which
showed that dexamethasone and tumor
necrosis factor a blocked the lethal effects
ofTCDD without effect on the magnitude
ofP450 enzyme induction.
There was considerable heterogeneity
in the cell proliferative responses as well as
in AHF development among individual
rats within each TCDD-treated group. For
example, in the 125 ng TCDD/kg/day
DEN-initiated group, approximately half
of the rats exhibited markedly elevated LI
(18-30%), whereas the other half were
only slightly higher than controls (5-10%;
Fig. 3). This difference was not correlated
with differences in hepatic TCDD concen-
tration, nor was it correlated with the mag-
nitude of CYPlAl or CYP1A2 induction
or histologic evidence ofcytotoxicity. Sim-
ilarly, it iS interestingt to that in the
chronic bioassay for TCDD carcinogenici-
ty in female Sprague-Dawley rats, approxi-
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mately half(40%) the rats at a dose of 100
ng TCDD/kg/day developed hepatocellu-
lar neoplasms (2). Any differences in AHF
response variability in the present study
versus a similar previous initiation-promo-
tion study (12,13) may be a reflection of
differences in the initiation protocols.
Although the mechanisms responsible for
interindividual differences in TCDD-
mediated increases in replicative DNA syn-
thesis rates and AHF formation are not
clear, there are some hints that signal trans-
duction events associated with growth fac-
tor pathways may be playing a role. For
example, TCDD does not induce cell pro-
liferation nor modulate epidermal growth
factor receptor actions in ovariectomized
rats, whereas significant changes in these
parameters are evident in intact female rats
(20, 24). These findings suggest that
TCDD and estrogens can act together to
generate a mitogenic signal, a hypothesis
that is supported by a recent study which
demonstrated that TCDD and estrogens
are co-mitogens in rat hepatocyte cultures
(39).
Data presented in this report attempt
to clarify the shape of the dose-response
curve for TCDD-mediated increases in cell
proliferation and PGST+ foci of cellular
alteration within the framework of a rat
liver tumor promotion model. Previous
studies have demonstrated that TCDD is a
potent promoter in two-stage models for
liver (40) and skin (41) cancer and that
chronic TCDD exposure enhances cell
proliferation rates in hepatocytes offemale
rats (206. While an increase in cell prolifer-
ation as estimated by LI was noted in the
DEN-initiated rats promoted with 125 ng
ofTCDD/kg/day, there was a decrease in
LI in the 3.5 ng ofTCDD/kg/day promot-
ed group, suggesting inhibition ofcell pro-
liferation at this low dose. Inhibition of
AHF formation at low doses ofTCDD has
been previous noted (12) and has also been
reported for phenobarbital promotion in
the rat (42). This is the first suggestion
that a similar phenomenon may be occur-
ring with respect to cell proliferation.
The dose range used in our studies is
consistent with the doses given in chronic
bioassays for carcinogenicity of TCDD
(approximately 1-100 ng/kg/day) (7,8).
Previous studies in our laboratory demon-
strated that few liver tumors develop after
30 weeks of TCDD promotion (100
ng/kg/day) of DEN-initiated rats (22).
However, after 60 weeks, approximately
50% of the female rats eventually devel-
oped tumors (both hepatocellular adeno-
mas and carcinomas) (24). Data presented
here are consistent with a previous study
(7) which showed that exposure of rats to
100 ng/kg/day for 30 weeks produced
increases in cell proliferation rates and
enzyme-altered foci. We extended that
finding by evaluating cell proliferation
rates and foci of cellular alteration follow-
ing lower chronic dosing with TCDD.
Results indicate that increases in PGST+
foci (mean volume and the proportion of
liver occupied by foci) and the LI were sta-
tistically significant only at a dose greater
than 100 ng/kg/day. Likewise, Pitot et al.
(12) have shown that significant increases
in the volume ofliver occupied by enzyme-
altered foci were not detected at doses less
than 100 ng TCDD/kg/day compared to
controls.
Taken together, these and our previous
studies (22,24) demonstrate that dose-
response relationships for TCDD's effects
on cell proliferation and growth ofAHF are
different from those for effects on P450
gene expression. This finding is consistent
with the conclusion that different biological
or biochemical responses requiring the same
receptor (Ah receptor) and the same ligand
(TCDD or its structural analogs) may
exhibit different dose-response relation-
ships. Thus, the shape ofthe dose-response
curve for receptor-mediated carcinogens
may not be predicted solely on the basis
that a response is receptor mediated.
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